Bloody, bold, and resolute: Dimensions of power in Hamlet, King Lear, and Macbeth
Bu tez size mi ait?
Bu kayıt toplu arşivden geldi. Sizinse profilinize bağlayın.
Özet (EN)
This thesis argues that there is a symbiotic relationship between the actions of characters making use of different aspects of power, and the plot progression in three tragedies by William Shakespeare; Hamlet, King Lear, and Macbeth, whose plots were built upon a problem of succession. For this purpose, the Aristotelian definition of tragedy was used in conjunction with the notion of power as defined by Steven Lukes throughout the study. To identify how this interaction helps build the dramatic structure, Thomas Pavel's concept of move was utilised to pinpoint the plot progression in the three plays. The first part describes the theoretical framework within which the study was conducted, with the second part providing an analysis of the plots of the three plays in relation to the actions by characters and how they act utilising various dimensions of power to serve their attempts at seizing sovereignty.
Yazar
Utku Tönel
Bu Yayına Nasıl Atıf Yapılır
Utku Tönel (Master Thesis). Bloody, bold, and resolute: Dimensions of power in Hamlet, King Lear, and Macbeth, 2023, Yeditepe University.
Anahtar Kelimeler
Lisans
Tüm Hakları Saklıdır
Bu eser belirtilen lisans koşulları altında paylaşılmaktadır.
Yeditepe University tezlerinden daha fazlası
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)